BHVN · Biohaven Ltd.
$14.64
-0.21 (-1.41%)
At close · Aug 14
Market Cap
$2.21B
Shares
151.04M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$738.82M
+12.7%
FY2025
Diluted EPS
-$6.86
+26.1%
FY2025
Operating Cash Flow
-$609.44M
-4.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $467.76M | $635.07M | $795.87M | $373.28M | $437.07M | $181.49M | $98.46M | |
| $99.69M | $110.31M | $89.24M | $62.77M | $130.86M | $37.41M | $16.05M | |
| — | $9.92M | $7.86M | $6.91M | $1.39M | $1.39M | $72K | |
| — | — | — | — | $567.93M | $218.9M | $114.51M | |
| $567.44M | $745.38M | $885.11M | $436.05M | $567.93M | $218.9M | — | |
| -$567.44M | -$745.38M | -$885.11M | -$436.05M | -$567.93M | -$218.9M | -$114.51M | |
| -$18.16M | $8M | $39.42M | $26.5M | -$1.91M | $6.47M | -$4.16M | |
| — | — | — | $0 | $0 | $5.26M | -$4.16M | |
| -$585.61M | -$737.38M | -$845.69M | -$409.55M | -$569.84M | -$212.43M | -$118.67M | |
| $1.24M | $1.44M | $735K | -$1.38M | $438K | $1.37M | $0 | |
| -$586.84M | -$738.82M | -$846.42M | -$408.17M | -$570.28M | -$213.8M | -$118.67M | |
| -$581.46M | -$730.55M | -$846.28M | -$408.52M | -$570M | -$213.8M | -$118.67M | |
| USD/shares | — | -$6.86 | -$9.28 | -$5.73 | -$12.75 | -$5.43 | -$3.01 |
| USD/shares | — | -$6.86 | -$9.28 | -$5.73 | -$12.75 | -$5.43 | -$3.01 |
| shares | 150.64M | 107.62M | 91.23M | 71.2M | 44.74M | 39.38M | 39.38M |
| shares | — | 107.62M | 91.23M | 71.2M | 44.74M | 39.38M | 39.38M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.30×
EV/EBIT
—
Peer median 22.07×
P/E (TTM)
—
Peer median 16.98×
Peer medians compare against the 260 similar-size Biotechnology companies (of 545 listed).
Key facts
CIK
1935979
CUSIP
G1110E107
13F (30d)
273 filings
271 filers
Visit website
Investor relations